|

Early Feasibility Study - Edwards APTURE Transcatheter Shunt System

RECRUITINGN/ASponsored by Edwards Lifesciences
Actively Recruiting
PhaseN/A
SponsorEdwards Lifesciences
Started2018-07-31
Est. completion2027-04
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations19 sites

Summary

The purpose of this study is to evaluate initial clinical safety, device functionality and effectiveness of the Edwards APTURE transcatheter shunt system.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Refined HFrEF Subgroup Inclusion Criteria:

* A primary diagnosis of HFrEF (LVEF ≤ 40%), and
* NYHA Class II, III, or IVa heart failure symptoms and
* Documentation of at least one of the following in the past 12 months, such as:

  * Hospitalization for heart failure; or
  * Increased treatment for heart failure, including intravenous (IV) or higher-dose diuretic therapy.
  * Elevated heart failure biomarker levels (BNP or NT-proBNP) within the past 6 months.

Note: Participants with NYHA Class II symptoms must have both a recent heart failure worsening event and elevated biomarker levels. Participants with NYHA Class III or IVa symptoms must have either a recent heart failure worsening event or elevated biomarker levels.

* Stable Optimized GDMT - Maintained 6 months post-implant (includes stable GLP-1 RA)

Refined HFrEF Subgroup Exclusion Criteria:

* Severe HF defined as one or more of the following:

  * Ambulatory NT-proBNP value \>5,000 pg/ml or BNP value \>1,600 pg/ml
  * Left ventricular end-diastolic diameter (LVEDD) \>8 cm
  * Left ventricular ejection fraction (LVEF) \< 20%
  * ACC/AHA Stage D HF or non-ambulatory NYHA Class IV HF
  * Inotropic infusion (continuous or intermittent) within the past 6 months
  * Active listing on the cardiac transplant waiting list
* More than mild right ventricular dysfunction
* Valve disease

  * Mitral regurgitation \> moderate
  * Mitral stenosis \> mild
  * Tricuspid regurgitation \> moderate
  * Aortic regurgitation \> moderate
  * Aortic stenosis \> moderate
* Body mass index (BMI) ≥45
* Myocardial infarction and/or any therapeutic invasive, non-valvular cardiac procedure within the past 3 months, or current indication for coronary revascularization
* Stroke, transient ischemic attack, deep vein thrombosis, or pulmonary embolus within the past 6 months
* Cardiac resynchronization therapy implanted within the past 12 months
* Renal insufficiency as determined by serum creatinine (sCr) level \>2.5 mg/dL or estimated glomerular filtration rate (eGFR) \<25 ml/min/1.73 m2
* Performance of the 6-minute walk test with a distance \<100 m or \>450 m
* Active endocarditis or infection requiring intravenous antibiotics within 3 months of scheduled index procedure
* Presence of one or more of the following resting hemodynamic findings:

  1. Mean pulmonary capillary wedge pressure (PCWP) \>35 mmHg
  2. Mean right atrial pressure (RAP) \>15 mmHg
  3. Mean PCWP-mean RAP gradient \< 5 mmHg
  4. Pulmonary vascular resistance (PVR) ≥5 Wood Units (WU)
  5. Cardiac index \<1.8 L/min/m2

Conditions2

Heart DiseaseHeart Failure

Locations19 sites

UC San Diego Health
La Jolla, California, 92037
Cedars Sinai Medical Center
University California San Francisco
University of Colorado
Aurora, Colorado, 80045
University of Florida Health - Jacksonville

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.